Drug Profile
FROST 600
Alternative Names: FROST-600Latest Information Update: 12 Sep 2023
Price :
$50
*
At a glance
- Originator Frost Biologic
- Class Antineoplastics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Mantle-cell lymphoma
Highest Development Phases
- Discontinued Mantle-cell lymphoma
Most Recent Events
- 12 Sep 2023 Discontinued - Preclinical for Mantle-cell lymphoma in USA (unspecified route)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Mantle-cell-lymphoma in USA
- 28 Jul 2016 FROST 600 is available for licensing as of 28 Jul 2016. http://www.frostbiologic.com/